News

Axios on MSN12d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
BioPharma Dive12d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
STAT12d
New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Science-Based Medicine11dOpinion
Dr. Vinay Prasad is Now the Medical Establishment. It’s His Job to Run RCTs, and It’s Our Job to Call Him a Lying Piece of $#!& if He Fails.
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
BioSpace12d
Vinay Prasad’s FDA Appointment ‘Anything but Status Quo’
The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...
MedPage Today on MSN12dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
U.S. News & World Report13d
Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research. The division oversees vaccines and biologic ...
New York Post14d
FDA names oncologist Vinay Prasad as top vaccine official
The US Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized COVID-19 restrictions, as the director of its Center for Biologics Evaluation and Research ...